NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?

Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Smolenschi, Cristina, Colomba, Emeline, Rassy, Elie, Lezghed, Naima, Kettab, Mohamed, Louvel, Guillaume, Garcia, Gabriel, Cheaib, Bianca, Bockel, Sophie, Pallud, Johan, Dezamis, Edouard, Copaciu, Razvan, Knafo, Steven, Ammari, Samy, Dhermain, Frederic, Domont, Julien, Martanovschi, Larisa, Mahmoud, Fekih, Dumont, Sarah
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Outcome Measures and Neuro-Cognitive Outcomes
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651623/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.558
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars